Elias Jabbour, MD
M.D. Anderson Cancer Center · MDA · UT MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
17
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in chronic myeloid leukemia
0
PubMed author-name match
Trials
Studies that name Elias Jabbour, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:06 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07192237 · Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · suspended · Phase 2 Study, Blinatumomab, Acute Lymphoblastic Leukemia · principal investigator
- Ph1/Ph2NCT07153796 · A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · active not recruiting · B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT07053059 · Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)M.D. Anderson Cancer Center · recruiting · Acute Lymphocytic Leukemia (ALL) · principal investigator
- Ph1/Ph2NCT06287229 · Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomabM.D. Anderson Cancer Center · recruiting · Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia · principal investigator
- Ph2NCT06236724 · Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.M.D. Anderson Cancer Center · recruiting · Chronic Myeloid Leukemia · principal investigator
- Ph2NCT02689440 · Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous LeukemiaM.D. Anderson Cancer Center · active not recruiting · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia · principal investigator
- Ph2NCT02199184 · Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · completed · AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements · principal investigator
- Ph2NCT02159872 · Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) FailureM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1NCT02141477 · Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph2NCT01746836 · Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or NilotinibM.D. Anderson Cancer Center · recruiting · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive · principal investigator
- Ph2NCT01720225 · Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 RiskM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT01685021 · Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)MorphoSys AG · terminated · Acute Lymphoblastic Leukemia · principal investigator
- Ph1/Ph2NCT01596127 · Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous SystemM.D. Anderson Cancer Center · terminated · Leukemia, Lymphoid Malignancies, Metastatic Malignant Neoplasm to the Leptomeninges · study chair
- Ph1/Ph2NCT01371630 · Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · recruiting · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt-Like Lymphoma With 11q Aberration · principal investigator
- Ph2NCT01319981 · Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1/Ph2NCT01289457 · Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT01019317 · Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · completed · Leukemia, AML, MDS · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in chronic myeloid leukemia.